NSE filing, NSE: SENORES. Summary written from the filing by ALFA Finder's alert engine.
Senores Pharmaceuticals Ltd: key numbers
- Share price
- ₹1,147.50
- Market cap
- ₹5,285 Cr
- Revenue (annual)
- ₹632.6 Cr
- Net profit (annual)
- ₹115.4 Cr
- P/E (TTM)
- 39.6×Sector 47.2×
- Promoter holding
- 45.82%+0.00% QoQ
- FII holding
- 6.01%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Senores Pharmaceuticals Ltd
All →Senores Pharmaceuticals Earnings Call Transcript: Key Takeaways
Senores delivered record quarterly revenue and EBITDA, driven by US portfolio expansion and regulated market growth.
- Call
- Guides 40% growth
Senores Pharmaceuticals Other Announcement
Senores Pharmaceuticals reported no deviation in utilising the Rs 95 Crore raised via a preferential warrant issue for the quarter ended September 30, 2026. Audit Committee reviewed the statement and the Board took it on record.
- Value
- ₹95.00 Cr
Senores Pharmaceuticals Capacity Expansion: ₹20 Cr Investment
Senores Pharmaceuticals' subsidiary Apnar Pharma Private Limited plans a 0.7 Bn unit capacity addition by March 2027. The investment is Rs.20.00 Crore, funded by internal accruals and IPO proceeds.
- Value
- ₹20.00 Cr
- Execution
- By end of March 2027
- production capacity
- 0.7 Bn units
Senores Pharmaceuticals Capacity Expansion: ₹18 Cr Investment
Senores Pharmaceuticals plans to add 0.8 Bn units of capacity to its existing 1.2 Bn unit plant by March 2027. The investment is Rs.18.00 Crore, funded by internal accruals and IPO proceeds.
- Value
- ₹18.00 Cr
- Execution
- By end of March 2027
- production capacity
- 0.8 Bn units
Senores Pharmaceuticals Other Announcement
Senores Pharmaceuticals appointed Talati and Talati LLP as Statutory Auditor for a 60-month term, effective 29 October 2026. The appointment was approved at the board meeting held the same day.
- Execution
- 60 months
Senores Pharmaceuticals Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹192.3 Cr (+24.9%), EBITDA ₹57.7 Cr (+38.3%, 30.0% margin), PAT ₹36.6 Cr. H1 revenue +30%, EBITDA +58.2%.
Other financial results announcements
All →Summit Securities Q2 FY27 Results: Net Profit ₹37 Cr, Up 2.2% YoY
Summit Securities Ltd reported revenue from operations of ₹51 Cr (+9.0% YoY) and net profit of ₹37 Cr (+2.2% YoY) for Q2 FY27.
- Key figure
- Net profit ₹37 Cr · +2.2% YoY
Simplex Mills Company Q2 FY27 Results: Net Profit ₹0 Cr
Simplex Mills approved unaudited results for the quarter ended 30 September 2026, reporting a net loss of Rs.3.94 Lakhs. Revenue from operations was Rs.6.30 Lakhs.
- Key figure
- Net profit ₹0 Cr
Veritas (India) Q2 FY27 Results: Net Loss of ₹5.5 Cr
Veritas (India) Ltd reported revenue from operations of ₹712.4 Cr (-29.2% YoY) and a net loss of ₹5.5 Cr for Q2 FY27.
- Key figure
- Net loss ₹5.5 Cr
Sharp Investments Q2 FY27 Results: Turns Profitable, Net Profit ₹0.2 Cr
Sharp Investments approved unaudited results for the quarter and half-year ended 30 Sept 2026. Profit before tax was Rs.42.60 Lacs for the half year.
- Key figure
- Net profit ₹0.2 Cr
Techknowgreen Solutions H1 FY27 Results: Net Profit ₹4.4 Cr, Up 46.7% YoY
Techknowgreen Solutions Ltd reported revenue from operations of ₹24.6 Cr (+46.4% YoY) and net profit of ₹4.4 Cr (+46.7% YoY) for H1 FY27.
- Key figure
- Net profit ₹4.4 Cr · +46.7% YoY
Ajmera Realty & Infra India Q2 FY27 Results: Net Profit ₹45 Cr, Up 48.0% YoY
Ajmera Realty & Infra India Ltd reported revenue from operations of ₹317 Cr (+44.7% YoY) and net profit of ₹45 Cr (+48.0% YoY) for Q2 FY27.
- Key figure
- Net profit ₹45 Cr · +48.0% YoY